MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
35.26
+1.17
+3.43%
After Hours: 35.26 0 0.00% 16:31 06/26 EDT
OPEN
34.06
PREV CLOSE
34.09
HIGH
35.47
LOW
33.77
VOLUME
4.79M
TURNOVER
--
52 WEEK HIGH
35.79
52 WEEK LOW
19.52
MARKET CAP
2.77B
P/E (TTM)
-8.2634
1D
5D
1M
3M
1Y
5Y
1D
Celldex Shareholders Approve Expanded Equity Incentive Plan
TipRanks · 1d ago
Celldex Therapeutics shareholders approve 3,400,000-share increase to 2021 equity plan at annual meeting
PUBT · 1d ago
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
TipRanks · 5d ago
Weekly Report: what happened at CLDX last week (0615-0619)?
Weekly Report · 5d ago
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
NASDAQ · 06/19 09:09
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION), Celldex (CLDX) and Jazz Pharmaceuticals (JAZZ)
TipRanks · 06/18 11:50
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 06/15 14:01
Celldex Presents New Phase 2 CSU Data For Barzolvolimab In Angioedema; BLA Planned For 2027
NASDAQ · 06/15 13:17
More
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Webull offers Celldex Therapeutics Inc stock information, including NASDAQ: CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.